Abstract
Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies.
MeSH terms
-
Aminoquinolines / adverse effects*
-
Aminoquinolines / therapeutic use
-
Antimalarials / adverse effects
-
Antiviral Agents / adverse effects*
-
Betacoronavirus
-
COVID-19
-
Chloroquine / adverse effects*
-
Coronavirus Infections / drug therapy*
-
Humans
-
Hydroxychloroquine / adverse effects*
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
SARS-CoV-2
Substances
-
Aminoquinolines
-
Antimalarials
-
Antiviral Agents
-
Hydroxychloroquine
-
Chloroquine
-
4-aminoquinoline